Cost-utility of chelators in transfusion-dependent β-thalassemia major patients: a review of the pharmacoeconomic literature.

@article{Lee2014CostutilityOC,
  title={Cost-utility of chelators in transfusion-dependent β-thalassemia major patients: a review of the pharmacoeconomic literature.},
  author={Todd A. Lee and Sarah Jane von Riedemann and Fernando Tricta},
  journal={Expert review of pharmacoeconomics & outcomes research},
  year={2014},
  volume={14 5},
  pages={651-60}
}
In the inherited hematologic disorder β-thalassemia major, patients receive regular, lifelong blood transfusions, which carry excess iron that the body is unable to eliminate. Chelation therapy (deferoxamine, deferiprone, deferasirox or deferoxamine-deferiprone combination) is required to reduce iron accumulation in target organs and the associated morbidity and mortality. Each chelation regimen has a distinct safety/efficacy profile and particular costs associated with its use. This review… CONTINUE READING